IMMUNOHISTOCHEMICAL LOCALIZATION OF P-GLYCOPROTEIN IN ADULT HUMAN OVARY AND FEMALE GENITAL-TRACT OF PATIENTS WITH BENIGN GYNECOLOGICAL CONDITIONS

被引:26
作者
FINSTAD, CL
SAIGO, PE
RUBIN, SC
FEDERICI, MG
PROVENCHER, DM
HOSKINS, WJ
LEWIS, JL
LLOYD, KO
机构
[1] MEM SLOAN KETTERING CANC CTR,DEPT PATHOL,NEW YORK,NY 10021
[2] MEM SLOAN KETTERING CANC CTR,DEPT SURG,GYNECOL SERV,NEW YORK,NY 10021
关键词
Cervix; Corpus luteum; Fallopian tube; Human adult ovary; Multidrug resistance; P-glycoprotein;
D O I
10.1177/38.11.1976674
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The multidrug-resistance gene, MDR1, encodes a plasma membrane glycoprotein termed P-glycoprotein, which mediates active cellular efflux of certain cytotoxic agents. Two mouse monoclonal antibodies (MAb), C219 and JSB-1, were used to identify P-glycoprotein in frozen tissue from the female genital tract of 14 women with benign gynecological conditions; multiple samples from several sites in the genital tract were available from seven patients. P-glycoprotein was detected in the ovarian surface epithelium in four of 14 cases, in the Fallopian tube in three of five cases, in occasional epithelial cells of the endometrial glands in two of five cases, in some endocervical glandular epithelium in three of five cases, in ectocervical squamous epithelium in one of the two cases, and in luteinized cells of the eight cases in which a corpus luteum was present in the specimen. Positive staining with these two MAb was also observed in some endothelial cells in the cortex of the ovary and in the stromal tissue of the myometrium, endometrium, and endocervix. These studies suggest that, if epithelial ovarian cancers are derived from the surface epithelial cells of the ovary, a small proportion of the cancers might be expected to retain the phenotype found in non-cancerous cells and to express P-glycoprotein.
引用
收藏
页码:1677 / 1681
页数:5
相关论文
共 32 条
  • [1] THE GENE ENCODING MULTIDRUG RESISTANCE IS INDUCED AND EXPRESSED AT HIGH-LEVELS DURING PREGNANCY IN THE SECRETORY EPITHELIUM OF THE UTERUS
    ARCECI, RJ
    CROOP, JM
    HORWITZ, SB
    HOUSMAN, D
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (12) : 4350 - 4354
  • [2] DETECTION OF P-GLYCOPROTEIN IN OVARIAN-CANCER - A MOLECULAR MARKER ASSOCIATED WITH MULTIDRUG RESISTANCE
    BELL, DR
    GERLACH, JH
    KARTNER, N
    BUICK, RN
    LING, V
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1985, 3 (03) : 311 - 315
  • [3] BIEDLER JL, 1970, CANCER RES, V30, P1174
  • [4] BOURHIS J, 1989, CANCER RES, V49, P5062
  • [5] INTERNAL DUPLICATION AND HOMOLOGY WITH BACTERIAL TRANSPORT PROTEINS IN THE MDR1 (P-GLYCOPROTEIN) GENE FROM MULTIDRUG-RESISTANT HUMAN-CELLS
    CHEN, CJ
    CHIN, JE
    UEDA, K
    CLARK, DP
    PASTAN, I
    GOTTESMAN, MM
    RONINSON, IB
    [J]. CELL, 1986, 47 (03) : 381 - 389
  • [6] CORDONCARDO C, 1989, CANCER CEL, V7, P87
  • [7] MULTIDRUG-RESISTANCE GENE (P-GLYCOPROTEIN) IS EXPRESSED BY ENDOTHELIAL-CELLS AT BLOOD-BRAIN BARRIER SITES
    CORDONCARDO, C
    OBRIEN, JP
    CASALS, D
    RITTMANGRAUER, L
    BIEDLER, JL
    MELAMED, MR
    BERTINO, JR
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (02) : 695 - 698
  • [8] EXPRESSION OF A MULTIDRUG-RESISTANCE GENE IN HUMAN-TUMORS AND TISSUES
    FOJO, AT
    UEDA, K
    SLAMON, DJ
    POPLACK, DG
    GOTTESMAN, MM
    PASTAN, I
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (01) : 265 - 269
  • [9] COMPARISON OF WESTERN BLOT ANALYSIS AND IMMUNOCYTOCHEMICAL DETECTION OF P-GLYCOPROTEIN IN MULTIDRUG RESISTANT CELLS
    FRIEDLANDER, ML
    BELL, DR
    LEARY, J
    DAVEY, RA
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 1989, 42 (07) : 719 - 722
  • [10] EXPRESSION OF A MULTIDRUG RESISTANCE GENE IN HUMAN CANCERS
    GOLDSTEIN, LJ
    GALSKI, H
    FOJO, A
    WILLINGHAM, M
    LAI, SL
    GAZDAR, A
    PIRKER, R
    GREEN, A
    CRIST, W
    BRODEUR, GM
    LIEBER, M
    COSSMAN, J
    GOTTESMAN, MM
    PASTAN, I
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1989, 81 (02) : 116 - 124